08:00 , Jan 26, 2009 |  BC Week In Review  |  Company News

Akesis endocrine news

Akesis will file for Chapter 7 bankruptcy after discontinuing development of AKP-020, its sole clinical program. The vanadium insulin-enhancer was in Phase IIa testing to treat Type II diabetes. The company said a review of...
07:00 , Oct 16, 2008 |  BC Innovations  |  Cover Story

Spiking diabetes

U.S. and Australian researchers have unraveled a mechanism that could explain the correlation between transient spikes in glucose levels and an increased risk for cardiovascular complications in diabetes patients.1 The findings could change the way...
07:00 , Jul 28, 2008 |  BC Week In Review  |  Company News

Akesis scientific advisory board update

Akesis Pharmaceuticals Inc. (OTCBB:AKES), La Jolla, Calif.   Business: Endocrine   Appointed: Christos Mantzoros, associate professor of medicine at Harvard Medical School and associate professor in the department of environmental health at the Harvard School of Public...
07:00 , Jul 7, 2008 |  BC Week In Review  |  Company News

Akesis management update

Akesis Pharmaceuticals Inc. (OTCBB:AKES), La Jolla, Calif.   Business: Endocrine   Hired: Carl LeBel, a director, as president and COO, formerly executive director for program management and strategic operations at Amgen Inc.; he replaces current President...
07:00 , Jul 7, 2008 |  BioCentury  |  Finance

1H08 warrant coverage

1H08 warrant coverage Company Offering share price Price prior to announcement Premium/discount Warrant coverage Raised ($M) Akesis (OTCBB:AKES) $0.85 $0.90 -6% 15% $2.0...
07:00 , Jun 23, 2008 |  BC Week In Review  |  Clinical News

AKP-020: Additional Phase IIa data

Data from 9 patients in a Phase IIa trial showed that AKP-020 significantly reduced fasting plasma glucose (FPG) levels from baseline (p<0.05) and nonsignificantly reduced FPG levels vs. placebo. Seven patients received 20 mg of...
07:00 , Jun 9, 2008 |  BC Week In Review  |  Clinical News

AKP-020: Completed Phase IIa enrollment

Akesis completed enrollment of 10 patients in a single-blind Phase IIa trial comparing 20 mg of oral AKP-020 with placebo. The company had originally planned to enroll 21 patients but decided to stop early to...
07:00 , Mar 24, 2008 |  BC Week In Review  |  Clinical News

AKP-020: Preliminary Phase IIa data

Preliminary data from a single-blind Phase IIa trial in the first four patients showed that treatment with AKP-020 reduced plasma glucose levels in the fasted state and two hours after an OGTT vs. placebo. For...
08:00 , Mar 3, 2008 |  BC Week In Review  |  Clinical News

AKP-020: Phase IIa started

Akesis began a single-blind, placebo-controlled, U.S. Phase IIa trial in 21 patients. The company licensed exclusive rights to AKP-020 from the University of British Columbia. Akesis Pharmaceuticals Inc. (OTCBB:AKES), La Jolla, Calif.   Product: AKP-020   Business:...
08:00 , Feb 25, 2008 |  BioCentury  |  Finance

Ebb & Flow

Encysive (NASDAQ:ENCY) has never disclosed exactly what the FDA doesn't like about the company's Phase III data on Thelin sitaxsentan, which has received three FDA approvable letters for pulmonary arterial hypertension (PAH) despite already being...